FDA Issues Warning About Vivitrol Injection Site Reactions

OPEN MINDS On-Line News Mental Health & Chemical Dependency Services On August 12, 2008, the U.S. Food and Drug Administration (FDA) issued a warning that Vivitrol (naltrexone in an extended-release injectable suspension) used to treat alcohol addiction had been linked to abscesses at the injection site. The FDA said it received 196 reports of injection site reactions ranging from cellulitis to necrosis; 16 cases required surgical intervention to treat the infection. The reactions were related to improper injection techniques, and the risk of serious reactions increased when the drug was deposited in subcutaneous or fatty tissue. The . . .